You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

22 search results for: exacerbations

<b>Exacerbations</b> Lead to Worsening Lung Function

expert video

Exacerbations Lead to Worsening Lung Function

2 min

Type 2 Inflammation

Dr. Mario Castro discusses how COPD exacerbations can predict future exacerbations and lead to progressive lung function loss in COPD patients.

expert video

Impact of Exacerbations in COPD

2 min

Type 2 Inflammation

Dr. Stephanie Christenson discusses the association between COPD exacerbations and the increased risks of morbidity and mortality

What Differentiates COPD <b>Exacerbations</b> From Asthma <b>Exacerbations</b>?

expert video

What Differentiates COPD Exacerbations From Asthma Exacerbations?

2 min

Pulmonology

Join global expert Dr. Eric Bateman as he discusses how exacerbations in patients with COPD are different than exacerbations in patients with asthma.

expert video

Clinical Manifestations Associated With Airway Remodeling in Asthma

2 min

Type 2 Inflammation

Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.

Infographic

Blood Eosinophils: A Biomarker in COPD

14 min

Pulmonology

In COPD, blood eosinophil testing is one of the five core assessments for initial patient evaluation, according to the GOLD Report. This infographic illustrates the role that blood eosinophils, as a biomarker for type 2 inflammation, play in predicting exacerbation risk and other COPD outcomes, and provides information from the GOLD Report on when to test for blood eosinophils and how eosinophils may guide patient management.

expert video

Systemic Inflammation in AD – Beyond the Skin

4 min

Dermatology

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel presents how systemic inflammation affects organ systems beyond the skin, and could potentially manifest as atopic and non-atopic comorbidities.

videoanimation

Importance of Lung Function Assessment in Adult Asthma Patients

3 min

Pulmonology

Review the burden associated with lung function decline in adult patients with severe asthma, and the value of clinical lung function assessments.

interactivity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

5 min

Pulmonology

Learn about the disease burden and heterogeneity of COPD.

expert video

What is the Role of FeNO as an Asthma Biomarker?

2 min

Pulmonology

Prof. Klaus Rabe and Dr. Michael Wechsler explore the utility of FeNO as a biomarker in asthma.

interactivity

Worsening Disease Results in a Vicious Cycle of COPD

5 min

Pulmonology

Learn about the disease burden and heterogeneity of COPD

expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

8 min

Pulmonology

Watch Prof G. Walter Canonica discuss the need to move beyond disease control to clinical remission in asthma and CRSwNP.

interactivity

Understanding IL-33: A Key Factor in COPD Pathogenesis

5 min

Pulmonology

Explore the role of IL-33 in COPD pathophysiology and its potential as a therapeutic target

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AlgeriaChange country/region